(818) 246-8000
Internal medicine physician reviewing weight management options with a patient at a Glendale clinic

Semaglutide vs Tirzepatide: How They Differ and What the Trials Found

NOVEMBER 16, 2026
Reviewed by Dr. Narbeh Tovmassian, MD, FACPDr. Narbeh Tovmassian, MD, FACP, founder of Elevate Health Group
9 MIN READ

Semaglutide and tirzepatide are the two prescription medications people in Los Angeles ask about most when the subject is injectable weight management. They are not the same drug. They do not act on the same receptors, their approved uses do not fully overlap, and only one clinical trial has compared them directly at maximum tolerated dose. Most of what circulates online skips all three of those points.

This article sets out what each medication is, which uses the FDA has approved, what that one head-to-head trial measured, and what each label warns about. It is written for someone deciding whether to raise either medication with a physician. It is not a recommendation of one over the other. Which medication suits a particular person, or whether either is appropriate at all, depends on medical history, current prescriptions, other conditions, and what a clinician finds at an evaluation.

What each medication actually is

Semaglutide is a GLP-1 receptor agonist. It acts on one receptor, the receptor for glucagon-like peptide-1. It is sold under the brand name Wegovy for weight reduction and under the brand name Ozempic for glycemic control in type 2 diabetes.

Tirzepatide acts on two receptors: GLP-1 and GIP, the receptor for glucose-dependent insulinotropic polypeptide. It is sold as Zepbound for weight reduction and as Mounjaro for type 2 diabetes. That second receptor is the mechanical difference between the two drugs, and it is the reason researchers expected different results rather than identical ones.

Both are given as a once-weekly injection. A daily oral tablet form of semaglutide was approved in December 2025. If you want the wider picture of how a supervised program is structured before comparing molecules, our explainer on how a GLP-1 weight loss program works covers the sequence of visits and monitoring.

The approved uses are not the same

This is the part that gets flattened into "two weight loss shots", and it matters clinically. Wegovy was first approved in June 2021 to reduce excess body weight in adults, extended in December 2022 to patients aged 12 and older with obesity. In March 2024 the FDA approved it to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease who also have obesity or overweight. In August 2025 it received accelerated approval for noncirrhotic metabolic dysfunction-associated steatohepatitis, MASH, with moderate to advanced liver fibrosis.

Zepbound was approved in November 2023 for chronic weight management. In December 2024 it became the first prescription medication approved for moderate to severe obstructive sleep apnea in adults with obesity.

So a person with established cardiovascular disease, or with diagnosed sleep apnea, or with MASH, may have a reason to discuss one specific medication that has nothing to do with how many pounds the trials reported. Every one of those approvals is written as a treatment used in combination with a reduced-calorie diet and increased physical activity. That phrasing is in the labeling itself, not an add-on from us.

What the one head-to-head trial found

SURMOUNT-5 is the trial that compared them directly. Its full results were published in the New England Journal of Medicine in 2025. It enrolled 751 adults with obesity who did not have type 2 diabetes, ran for 72 weeks, and compared tirzepatide at maximum tolerated dose, 10 or 15 mg, against semaglutide at maximum tolerated dose, 1.7 or 2.4 mg.

At 72 weeks the tirzepatide group had a mean body weight reduction of 20.2 percent against 13.7 percent in the semaglutide group, a difference the investigators reported as statistically significant. In absolute terms that was 22.8 kg against 15.0 kg. Mean waist circumference fell 18.4 cm against 13.0 cm. Discontinuation because of gastrointestinal side effects was lower on tirzepatide, 2.7 percent, than on semaglutide, 5.6 percent. The trial also reported smaller average reductions among men than among women in both groups.

Read those numbers for what they are. They are group averages at maximum tolerated dose over 72 weeks in people without type 2 diabetes. An average of 20.2 percent contains people who lost considerably more and people who lost considerably less. Diabetes status changes the picture on its own: in the tirzepatide trial program, average reduction at the 15 mg dose was lower among participants who had type 2 diabetes than among those who did not. A trial average is not a forecast for any individual.

Side by side

Semaglutide (Wegovy)Tirzepatide (Zepbound)
Drug classGLP-1 receptor agonistDual GIP and GLP-1 receptor agonist
First FDA approval for weight reductionJune 2021, adultsNovember 2023, adults
Other approved usesCardiovascular event risk reduction, 2024; noncirrhotic MASH with moderate to advanced fibrosis, 2025, accelerated approvalModerate to severe obstructive sleep apnea in adults with obesity, 2024
Same molecule, diabetes brandOzempicMounjaro
How it is takenOnce-weekly injection; a daily oral tablet was approved December 2025Once-weekly injection
SURMOUNT-5 mean weight change at 72 weeksDown 13.7 percentDown 20.2 percent
SURMOUNT-5 stopped for gastrointestinal side effects5.6 percent of participants2.7 percent of participants
Boxed warningRisk of thyroid C-cell tumorsRisk of thyroid C-cell tumors

What both labels warn about

The warnings overlap more than the marketing does. Points that appear on both labels:

  • A boxed warning for the risk of thyroid C-cell tumors, and a contraindication in anyone with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
  • Gastrointestinal reactions as the most common adverse effects: nausea, vomiting, diarrhea, constipation, abdominal pain. These are the reactions that most often end treatment.
  • Acute pancreatitis, acute gallbladder disease, acute kidney injury from volume depletion, and serious hypersensitivity reactions including anaphylaxis and angioedema.
  • A higher risk of low blood sugar when taken alongside insulin or an insulin secretagogue, which may mean those doses have to be reduced.
  • Pulmonary aspiration during general anesthesia or deep sedation. This is the reason to tell every clinician, including a dentist or surgeon, that you are on one of these medications before any planned procedure.
  • Delayed gastric emptying, which can change how other oral medications are absorbed.
  • Diabetic retinopathy complications in people who have type 2 diabetes.

One asymmetry worth knowing: the Zepbound label lists suicidal behavior and ideation among its warnings and precautions. If you have a history of depression or suicidal thoughts, say so at the evaluation rather than at a later visit.

What "which one is better" leaves out

The head-to-head number is the easiest thing to quote and the least useful thing to decide on alone. Several factors sit above it.

  • Tolerability. The medication with the stronger trial average is worth nothing to someone who cannot stay on it. SURMOUNT-5 measured this directly, and it went in tirzepatide’s favor, but individuals are not averages.
  • Your other conditions. Cardiovascular disease, sleep apnea, MASH and type 2 diabetes each point toward a specific approved use rather than a general preference.
  • Your other prescriptions. Both drugs slow gastric emptying, which matters for any oral medication with a narrow therapeutic range.
  • Coverage. Plan formularies differ and change, and the approved use on your prescription affects whether a plan pays. Our guide to insurance and medical weight loss lists the questions to put to your insurer before you start.
  • What the weight is made of. The scale does not separate fat from muscle. An InBody body composition assessment does, and repeating it is how you find out whether a program is working the way it should. Our post on body composition scans during weight loss explains what the readout shows.
  • What happens afterwards. The trials ran 68 or 72 weeks. Both labels describe these medications as treatments to reduce weight and maintain the reduction long term, which tells you maintenance is a separate conversation, not an afterthought.
  • Who is supervising. A prescription issued after a web form is not an evaluation. We set out the difference in doctor-led versus online weight loss programs.

How supervision works at Elevate Health Group

Our medical weight loss program is run by board-certified internal medicine physicians, not by a prescriber you never meet. The sequence is an evaluation first: history, a review of every current prescription, and bloodwork through our on-site laboratory so results come back within the same episode of care rather than weeks later.

Only after that does the question of medication come up, and the first honest answer is sometimes that a GLP-1 based medication is not the right step yet. If it is appropriate, dose changes happen on a monitored schedule at follow-up visits, with side effects reviewed each time. We deliberately do not publish dose schedules: escalation is a clinical decision made for one person, not a chart to follow at home. Our tirzepatide program page describes what is included, and our earlier article on tirzepatide for weight loss in Los Angeles covers the practical side of starting.

When you call, ask which product and formulation the practice dispenses and what the monthly figure covers. That is a fair question to ask any clinic, and a clinic that will not answer it plainly is telling you something.

Service Area

Elevate Health Group sees patients at three offices: Glendale, Burbank and La Cañada. Weight management visits are available at our offices across the greater Los Angeles area, including Pasadena, Burbank, Glendale and the surrounding foothill communities.

Frequently Asked Questions

Need Help? Find Answers Here

In SURMOUNT-5, the one trial that compared them head to head at maximum tolerated dose, the tirzepatide group lost more weight on average and fewer participants stopped because of gastrointestinal side effects. That is a finding about two groups over 72 weeks, not a prediction about you, and it says nothing about the uses where only one of the two is approved. "Better" depends on what you are treating and what you can tolerate.
That is a clinical decision, not a self-service one. Both labels state that these medications should not be taken alongside another GLP-1 receptor agonist or another product containing the same molecule, so any change has to be sequenced by the prescriber.
Every approved use for both drugs is written as treatment in combination with a reduced-calorie diet and increased physical activity. The trials were run that way. There is no version of the evidence in which the injection is the whole intervention.
It depends on your plan and on the approved use your prescription is written for. Plans treat weight reduction, cardiovascular risk reduction and diabetes differently, and formularies change. Call the number on your card and ask about your specific plan year before you budget for anything.
Published withdrawal studies of GLP-1 medications have reported that weight tends to return after treatment stops. That is why both labels describe the goal as reducing weight and maintaining the reduction long term. Stopping is worth planning with your physician rather than doing abruptly.
No. Compounded preparations are not FDA-approved products and are not the products these trials studied. If a clinic offers a compounded version, ask what it contains, which pharmacy prepares it, and how it differs from the approved product, and get the answer before you agree to anything.

Talk to a physician before you choose

If you are weighing these medications, the useful next step is an evaluation rather than more reading. Contact our office to arrange a visit in Glendale, Burbank or La Cañada, and bring a list of everything you currently take.

This article is general health information, not medical advice, and reading it does not create a physician-patient relationship. The weight reduction figures quoted are averages from published clinical trials and are not a prediction of any individual result. Individual results vary. Prescription decisions are made by a licensed clinician after an evaluation. Discuss any medication with a qualified clinician before starting or stopping it.

November 16, 2026

YOU MIGHT ALSO ENJOY...